Literature DB >> 15287631

[Liver resection after downstaging with neoadjuvant chemotherapy for "unresectable" colorectal metastases].

Antonio Frena1, Federico Martin, Giuseppe La Guardia, Norberto Vezzali, Gianpietro Bonatti, Judith Stocker, Claudio Graiff.   

Abstract

Hepatic resection is the only treatment that offers a chance of long-term survival in patients with metastases from colorectal cancer. Nevertheless, a curative resection can be performed in only 10-20 per cent of patients: multiple bilobar metastases or "unresectable" disease are the greatest obstacles to surgical radicality. Techniques such as preoperative portal embolisation, preoperative portal ligation, two-stage hepatectomy, and neoadjuvant chemotherapy, have extended the possibility of liver surgery to patients with advanced metastatic colorectal cancer. The outcomes of two patients treated successfully with neoadjuvant chemotherapy (one case with FOL-F-OX, and one with FOL-F-IRI) followed by liver resection were analyzed. In both patients neoadjuvant chemotherapy enabled a curative liver resection to be performed without significant complications. In some patients, neoadjuvant chemotherapy permits the "downsizing" of metastatic disease to such an extent that a surgical approach proves feasible. This advance can dramatically improve the prognosis of patients with multiple or unresectable liver metastases from colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15287631

Source DB:  PubMed          Journal:  Chir Ital        ISSN: 0009-4773


  2 in total

1.  Postchemotherapy characteristics of hepatic colorectal metastases: remnants of uncertain malignant potential.

Authors:  Tamara L Znajda; Shinichi Hayashi; Peter J Horton; John B Martinie; Prosanto Chaudhury; Victoria A Marcus; Jeremy R Jass; Peter Metrakos
Journal:  J Gastrointest Surg       Date:  2006-04       Impact factor: 3.452

2.  Practical questions in liver metastases of colorectal cancer: general principles of treatment.

Authors:  Héctor Daniel González; Joan Figueras
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.